The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 698K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

28 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.EBI
Abbvie
Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.EBI
Abbvie
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.EBI
Genentech
3-Substituted-N-(4-hydroxynaphthalen-1-yl)arylsulfonamides as a novel class of selective Mcl-1 inhibitors: structure-based design, synthesis, SAR, and biological evaluation.EBI
University of Michigan Medical School
Discovery of potent and selective benzothiazole hydrazone inhibitors of Bcl-XL.EBI
The Walter and Eliza Hall Institute of Medical Research
Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.EBI
Mcgill University
Development of dimeric modulators for anti-apoptotic Bcl-2 proteins.EBI
University of Minnesota Minneapolis
Development of selective inhibitors for anti-apoptotic Bcl-2 proteins from BHI-1.EBI
University of Minnesota
Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.EBI
University of Washington
Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.EBI
The Walter and Eliza Hall Institute of Medical Research
Isosteric exchange of the acylsulfonamide moiety in Abbott's Bcl-XL protein interaction antagonist.EBI
University of Pittsburgh
Discovery and optimization of (2-naphthylthio)acetic acid derivative as selective Bfl-1 inhibitor.EBI
Tianjin University
Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.EBI
University of Minnesota
Inhibitors of BCL2A1/Bfl-1 protein: Potential stock in cancer therapy.EBI
China Pharmaceutical University
Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy.EBI
Shandong First Medical University & Shandong Academy of Medical Sciences
Discovery of a selective and covalent small-molecule inhibitor of BFL-1 protein that induces robust apoptosis in cancer cells.EBI
Yancheng Teachers University
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.EBI
Abbott Laboratories
Design and modular parallel synthesis of a MCR derived alpha-helix mimetic protein-protein interaction inhibitor scaffold.EBI
Abc Pharma
Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology.EBI
Amgen
Discovery of 3,5-Dimethyl-4-Sulfonyl-1EBI
China Pharmaceutical University
Discovery and optimization of covalent Bcl-xL antagonists.EBI
Astrazeneca
The chemical biology of apoptosis: Revisited after 17 years.EBI
Tsinghua University
Clinical candidates modulating protein-protein interactions: The fragment-based experience.EBI
Taros Chemicals
Structure-based design of rhodanine-based acylsulfonamide derivatives as antagonists of the anti-apoptotic Bcl-2 protein.EBI
Soochow University
Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules.EBI
University of Maryland
Substituted quinolines as PDE-10 inhibitorsBDB
Sunovion Pharmaceuticals
Synthesis and target identification of hymenialdisine analogs.BDB
Genomics Institute of The Novartis Research Foundation
 
AR-709-An Investigational diaminopyrimidine: Inhibition, Binding and Mode of Action.BDB
Arpida